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75 mg/m2 with GVHD prophylaxis of cyclosporin (CSA) and
mycophenolate (MMF). The median nucleated cell (NC) dose was
3.5  107/kg, 60% were 4/6 HLA mismatched. Sustained donor
engraftment was seen in 88% (95% CI: 83-97) at a median of 24
days. Complete donor chimerism was derived from one unit by day
60 in all but 4 patients. The incidence of grade III-IV acute
GVHD was 17% and chronic GVHD was 20%; TRM at 6 months
was 22%. With a median follow-up of 20 months, 2 yr survival and
DFS was 63% and 59%. 93 patients (median age: 52 years (range:
17-69) who were aged 45 or had preexisting co-morbidities
received non-myeloablative conditioning with CY 50 mg/kg, FLU
200 mg/m2/day and TBI 200 cGy followed by double UCBT.
GVHD prophylaxis also consisted of CSA and MMF. The median
NC dose was 3.7  107/kg with 61% having at least one 4/6 HLA
mismatched unit. Sustained donor engraftment was seen in 83% at
a median of 12 days with donor chimerism 90% by day 100. The
incidence of grade III-IV acute GVHD, CGVHD and TRM was
23%, 22%, and 15%, respectively. Probability of DFS at 2 years is
49% (95% CI: 38-60) with a median follow up of 19 months.
These results indicate that the co-infusion of two partially HLA
matched UCB units after myeloablative or non-myeloablative con-
ditioning results in a high incidence of engraftment, and low rates
of AGVHD, CGVHD and TRM. Randomized trials are required
to determine the relative beneﬁt of double UCBT as compared to
single UCBT or transplantation of HLA matched marrow.
5
DOUBLE CORD BLOOD TRANSPLANTATION IN ADULTS USING A
REDUCED INTENSITY CHEMOTHERAPY ONLY CONDITIONING REGIMEN
Ballen, Karen. Masachusetts General Hospital.
Umbilical cord blood is a useful stem cell source for patients
without matched donors. Adult cord blood transplantation is lim-
ited by the low cell dose in most individual cord blood units. Initial
studies using single cord blood units with a myeloablative condi-
tioning regimen reported a 100 day transplant related mortality of
over 40%. Double cord blood transplantation (two units adminis-
tered sequentially) provides a higher cell dose, and a reduced
intensity conditioning regimen may decrease transplant related
mortality.
We have treated 35 patients with this approach using a conditioning
regimen of ﬂudarabine 30 mg/m2/day days8 through3 (total dose
180 mg/m2), melphalan 100 mg/m2 day2 and rabbit antithymocyte
globulin 1.5 mg/kg days 7, 5, 3, 1 (total dose 6 mg/kg). Cord
blood units were a 4/6 or higher HLA A, B, DR allele match with the
patient and each other and achieved a minimum precryopreservation
cell dose of 3.7  107 NC/kg. Twenty one patients received GVHD
prophylaxis with cyclosporine and mycophenolate mofetil and four-
teen patients received GVHD prophylaxis with tacrolimus and siroli-
mus. Only ﬁve patients treated with sirolimus and tacrolimus have
greater than 100 days of follow up; the results with this GVHD
regimen will be reported subsequently.
For the cyclosporine/mycophenolate mofetil patients the median
days to neutrophil and platelet engraftment (platelet count greater
than 20,000 unsupported) were 20 and 41 days respectively. Fifteen of
21 patients are alive with a median follow up of 16 months. One
patient with CLL has progressive disease. The 100 day transplant
related mortality is 14%, with the deaths from post-transplant lym-
phoproliferative disorder, central nervous system bleeding, and staph-
ylococcal sepsis. One year disease free survival is 66%. Double cord
blood transplantation with a reduced intensity regimen may be a safer
option for patients requiring cord blood transplantation.
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RISK OF RELAPSE AFTER UMBILICAL CORD BLOOD TRANSPLANTATION
IN PATIENTS WITH ACUTE LEUKEMIA: MARKED REDUCTION IN
RECIPIENTS OF TWO UNITS
Verneris, Michael R., Brunstein, Claudio, DeFor, Todd E.,
Barker, Juliet, Weisdorf, Daniel J., Blazar, Bruce R., Miller, Jeffrey S.,
Wagner, John E. Blood & Marrow Transplant Program, University of
Minnesota, Minneapolis, MN.
We analyzed patients with acute leukemia transplanted with
myeloablative conditioning at a single institution to determine if
there were any unique risk factors associated with relapse after
UCBT. Ninety-six consecutive patients were evaluated, 39 were
18 years of age, 50 were male; 46 were CMV seropositive; 50
had ALL and 46 had AML. Two different conditioning regi-
mens were used. Regimen A consisted of cyclophosphamide 120
mg/kg, TBI 1320-1375 cGy, and ATG, followed by cyclospor-
ine A (CSA)/methylprednisolone immunosuppression (n  53).
Regimen B consisted of cyclophosphamide 120 mg/kg, ﬂudara-
bine 75 mg/m2, TBI 1320-1375 cGy pre-transplant and CSA/
mycophenolate mofetil immunosuppression (n  43). Patients
received either one (n  67) or two (n  29) 4-6/6 HLA-
matched UCB units, so that the total IVCNC count was 2.5 
107/kg. Accordingly, the demographics for recipients of one or
two UCB units were similar except for older age (median age 24
vs 8, P  0.01) and greater weight (median 70 vs 32 kg, P 
0.01) for recipients of two UCB units. Potential risk factors for
relapse that were evaluated included: age, gender, recipient
CMV sero-status, diagnosis, disease risk, HLA disparity, regi-
men (A vs B), and TNC (or CD34) dose of the unit responsible
for sustained engraftment.
Notably, in Cox regression analysis two factors were associated
with lower relapse risk: disease risk (CR1/CR2 vs CR3/REL [RR
0.32, P  0.02]) and transplantation of two UCB units (RR 0.3,
P  0.03). Importantly, the diagnosis, UCB graft cell dose, and
presence of acute GVHD had no demonstrable impact. All recip-
ients of regimen A received a single UCB unit (relapse was 28%
(95% CI, 15-41%)), thus interactions between regimen A and
number of UCB units could not be assessed. Patients who received
regimen B in CR1/2, showed a signiﬁcantly lower risk of relapse
with two UCB units compared to one unit (11% vs 54%, P 0.01).
No signiﬁcant difference in relapse risk could be discerned for
patients with advanced disease (CR3-REL) when comparing single
vs double UCBT (P  0.48).
This report is the ﬁrst suggesting that double unit UCB grafts
may be associated with reduced relapse risk in acute leukemia.
Larger studies are needed to conﬁrm this clinical experience and to
investigate the potential mechanisms by which double unit grafts
could mediate protection against relapse.
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MYELOABLATIVE SINGLE CORD TRANSPLANTS (SCT) VERSUS DUAL
CORD TRANSPLANTS (DCT) IN ADULTS WITH ACUTE LEUKEMIA
Wooford, Jonathan, Regan, Donna, Alonso, Mario, Creer, Michael H.
St. Louis Cord Blood Bank and Departments of Pathology/Lab Medicine
and Pediatrics, St. Louis University, St. Louis, MO.
Background: Combining 2 cord blood products overcomes the
total nucleated cell (TNC) dose limitation and may improve clin-
ical outcomes following allogeneic cord blood (CB) transplantation
in adults. We performed a retrospective case-control study in adult
patients with acute leukemia receiving myeloablative conditioning
and 1 or 2 cord blood units to identify potential causes for differ-
ences in clinical outcomes following SCT and DCT and product
characteristics predictive of long-term engraftment in DCT recip-
ients.
Study design: To evaluate 20 DCT cases, we selected 20 SCT
with the largest TNC dose as controls from a cohort of 103 adult
SCT patients. SCT and DCT were matched for age, sex, diagnosis,
disease status, ethnicity and body weight (0.11  P  0.78) ex-
cluding patients with graft failure or previous transplants.
Results: Administered TNC dose for DCT (3.7  107/kg) was
nearly 2-fold greater than SCT (1.9 107/kg, P 0.0001) with no
signiﬁcant differences in post-thaw TNC recovery (P  0.13).
Time to ANC500/uL for DCT was 17 days compared to 20 days
for SCT (P  0.02). For SCT, there were 9 and 11 patients with
1 or 2 Ag mismatch at HLA-A,B or DRB1, respectively, (mean 
1.6 Ag mismatch). Three-way comparison of both donors and
recipient for DCT also gave mean  1.6 Ag mismatch. Overall
survival (OS) at 12 months was 18% for SCT and 72% for DCT
(P 0.0001) with median duration of follow-up of18 months for
both SCT and DCT. OS was signiﬁcantly correlated with post-
thaw TNC dose for SCT (P  0.04) but not for DCT (P  0.88).
In the ﬁrst 100 days post-transplant, infection rates for SCT (65%)
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and DCT were similar (50%) with no signiﬁcant differences in
frequency of viral, fungal or bacterial infections (P  0.74). Most
importantly, infection was the primary cause of death at 100 days
for SCT (9/20) whereas for DCT, there were no infection-related
deaths! TNC and CD34 cell dose did not differ between engraft-
ing and non-engrafting units; however, we found that the engraft-
ing units had a lower absolute lymphocyte count (ALC) in 8/10
evaluable cases.
Conclusion: DCT is an effective approach to overcome the
TNC dose-limiting therapeutic beneﬁt of CB transplantation.
Although 100-day post-transplant infection frequency remains
high, deaths from infection are markedly reduced and OS is
signiﬁcantly improved in DCT recipients; however, additional
studies are needed to deﬁne the mechanism. For DCT, the
engrafting unit does not have a higher TNC or CD34 cell dose
but, paradoxically, a lower ALC dose may be predictive.
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HLA MATCHING FOR TRANSPLANTATION: LESSONS FROM BONE
MARROW
Confer, Dennis L. National Marrow Donor Program, Minneapolis, MN.
HLA matching strongly affects the outcome of unrelated donor
bone marrow transplantation. How these effects translate to other
hematopoietic cell sources, such as cord blood and peripheral
blood stem cells, is only partially clariﬁed. Much of the available
data concerning bone marrow transplantation comes from studies
published by the Japan Marrow Donor Program, the Fred
Hutchinson Cancer Research Center, and the National Marrow
Donor Program (NMDP). In general, the studies show that match-
ing for HLA A, B, C and DRB1 inﬂuences important endpoints
such as survival, engraftment and graft versus host disease. Al-
though antigen level matching is important, allele level mismatches
are also detrimental. Matching for HLA DQ is important in some
studies, but not in others. A clear role for HLA DP matching has
not been identiﬁed.
For bone marrow transplantation, the NMDP recommends 8
of 8 allele matching at HLA A, B, C and DRB1. If this level of
matching cannot be achieved, a single allele mismatch is pref-
erable over an antigen mismatch. At the present time, each locus
should be considered of equal weight, that is, no locus is clearly
more important than the others. When multiple mismatches are
unavoidable, it is unclear how to compare alleles and antigens,
e.g., are two mismatched alleles preferable to a single antigen?
More data are needed to answer this question [1-5].
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ANALYSIS OF 608 UMBILICAL CORD BLOOD (UCB) TRANSPLANTS:
HLA-MATCH IS A CRITICAL DETERMINANT OF TRANSPLANT-RELATED
MORTALITY (TRM) IN THE POST-ENGRAFTMENT PERIOD EVEN IN THE
ABSENCE OF ACUTE GRAFT-VS-HOST DISEASE (AGVHD)
Barker, J., Scaradavou, A., Stevens, C., Rubinstein, P. New York Blood
Center (NYBC) National Cord Program and Memorial Sloan-Kettering
Cancer Center, New York, NY.
With the recognition of the critical importance of UCB cell
dose upon hematopoietic recovery, neutrophil recovery after
UCB transplantation (UCBT) has improved. However, TRM in
the early post-engraftment period (days 30-180) remains a bar-
rier to transplant success. How graft characteristics impact upon
the risk for TRM during this period is important but has not
been well characterized. Therefore, we analyzed the impact of
cell dose and HLA-match upon TRM between days 30-180 in
recipients of single unit 3-6/6 HLA-A,B antigen and DRB1
allele matched UCBT who were transplanted for leukemia or
myelodysplasia with units from the National Cord Blood Pro-
gram and achieved sustained donor engraftment. Patients dying
from days 0 to 29 or those with primary or secondary graft
failure were excluded, and patients were censored at the time of
relapse.
Six hundred eight patients fulﬁlled study criteria and had a
median age of 9.0 years (range 0.4-58 years). The cumulative
incidence of TRM was 36% (95% CI: 32-39). Using 2.5-4.9  107
TNC/kg as the reference (n  229), the impact of cell dose was
analyzed. While patients (n  141) receiving a lower dose of
0.7-2.4 had a relative risk (RR) of TRM of 1.5 (P  0.009) during
this period, TRM in patients receiving higher doses were similar to
the reference [5.0-9.9 (n  160) RR 0.9, P  0.4; 10.0 (n  78)
RR 0.8, P  0.4)]. However, HLA-match had an impact upon
TRM at all levels of match [reference: 5/6 recipients (n 194); 6/6
(n  32) RR 0.3, P  0.063; 4/6 (n  342) RR 1.7, P  0.001; 3/6
(n 40) RR 2.2, P 0.003]. To exclude the possibility that disease
stage contributed to this ﬁnding, a multivariate Cox regression
analysis was performed that included TNC dose, HLA-match and
disease stage, and showed that low cell dose and HLA-mismatch
were the signiﬁcant predictors of TRM. Further, when patients
were divided into those without signiﬁcant aGVHD (only grade 0
or 1) (n  292) vs patients with grade 2-4 aGVHD (n  301), the
effect of HLA-match on TRM was most pronounced in those
without signiﬁcant aGVHD [reference: 5/6 recipients (n  102);
6/6 (n  25) RR 0.0, P  NS; 4/6 (n  151) RR 2.4, P  0.004;
3/6 (n  14) RR 2.8, P  0.050]. Of the transplant-related deaths
(n  60) from days 30-180 in this “without signiﬁcant aGVHD”
group, infection was reported to be a major cause of death in 36
(60%).
In summary, above the threshold of 2.5 107 TNC/kg, cell dose
has no demonstrable effect on the risk for day 180 TRM in the
post-engraftment period, whereas the adverse impact of HLA-
mismatch is both striking and retained even in the absence of
aGVHD. We postulate that the adverse effect of HLA-mismatch is
mediated not only by induction of aGVHD, but also by an effect
on immune reconstitution as manifested by death from infection.
These data have signiﬁcant implications for graft selection imply-
ing that both dose and HLA-match should be considered, and
investigation of how to “trade-off” each of these factors should be
a priority. Further, it argues that recipients of HLA-mismatched
grafts will require aggressive supportive care and strategies to
augment immune reconstitution. Finally, improved outcome in
UCBT may be dependent upon the ability to obtain units that are
both of sufﬁcient size and match which will require an increase in
the global UCB inventory.
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